CW December 2004
Volume 13Issue Number 12 December 2004 ISSN 10593802 A Phase II Trial for a Novel Class of Vascular-Targeting AgentA phase II trial is slated for a novel drug that reduces tumor blood flow in solid tumors. This drug will be used in combination with standard chemotherapeutic regimen carboplatin and paclitaxel.
Go to Previous Page Go to Next Page Source & Additional Reading Fred Driscoll, President and Chief Executive Officer of OXiGENE. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW December 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
